Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide

Few prognostic models in heart failure have been developed in typically elderly patients treated with modern pharmacological therapy and even fewer included simple biochemical tests (such as creatinine), new biomarkers (such as natriuretic peptides), or, especially, both. In addition, most models have been developed for the single outcome of all‐cause mortality.

[1]  J. Vander.  C-Reactive Protein Levels and Outcomes After Statin Therapy , 2006 .

[2]  T. Ueland,et al.  Inflammatory and anti‐inflammatory cytokines in chronic heart failure: Potential therapeutic implications , 2005, Annals of medicine.

[3]  T. McDonagh,et al.  N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.

[4]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[5]  K. Bibbins-Domingo,et al.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.

[6]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[7]  D. Mozaffarian,et al.  Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. , 2007, The American journal of cardiology.

[8]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[9]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[10]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[11]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[12]  K. Swedberg,et al.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. , 2003, European Heart Journal.

[13]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[14]  C. Yancy.  Predicting life expectancy in heart failure. , 2008, JAMA.

[15]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[16]  J. Pell,et al.  Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.

[17]  Salim Yusuf,et al.  A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. , 2004, The American journal of medicine.

[18]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[19]  Gregg C Fonarow,et al.  Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. , 2002, Journal of cardiac failure.

[20]  M. Hellmich,et al.  Prognostic impact of NT‐proBNP and renal function in comparison to contemporary multi‐marker risk scores in heart failure patients , 2008, European journal of heart failure.

[21]  Steven Hawken,et al.  Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study , 2008, The Lancet.

[22]  P. Poole‐Wilson,et al.  Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.

[23]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[24]  R. Prescott,et al.  Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. , 2002, Journal of the American College of Cardiology.

[25]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[26]  J. Heywood,et al.  Simple Clinical Criteria to Determine the Prognosis of Heart Failure , 2005, Journal of cardiovascular pharmacology and therapeutics.

[27]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[28]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[29]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[30]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[31]  J. McMurray,et al.  Anemia and Its Relationship to Clinical Outcome in Heart Failure , 2004, Circulation.

[32]  B. Pitt,et al.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.